1. Home
  2. VRAX vs ARTL Comparison

VRAX vs ARTL Comparison

Compare VRAX & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$2.76

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$0.73

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
ARTL
Founded
2013
2011
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
2.6M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
VRAX
ARTL
Price
$2.76
$0.73
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$1.00
N/A
AVG Volume (30 Days)
65.5K
173.0K
Earning Date
06-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.69
52 Week High
$13.19
$19.91

Technical Indicators

Market Signals
Indicator
VRAX
ARTL
Relative Strength Index (RSI) 48.51 32.33
Support Level $2.55 $0.71
Resistance Level $3.10 $1.87
Average True Range (ATR) 0.18 0.06
MACD -0.07 0.02
Stochastic Oscillator 42.61 13.56

Price Performance

Historical Comparison
VRAX
ARTL

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: